Compare Msci Inc (MSCI) vs Vaxcyte Inc. Common Stock (PCVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Vaxcyte Inc. Common Stock — how do they compare? Msci Inc trades at $560.52 (market cap $41.29B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Msci Inc is far larger — about 3.9× Vaxcyte Inc. Common Stock's market cap, and Msci Inc pays a 1.44% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 83 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| MSCI | PCVX | |
|---|---|---|
Market Cap | $41.29B | $10.51B |
Volume | 468,436 | 2,644,694 |
Sector | Financials | Health |
52-Week High | $643.83 | $73.82 |
52-Week Low | $511.84 | $40.32 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $47.46B | $9.14B |
Dividend Yield | 1.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $560.52, down 1.32% today, with strong profitability (40.73% net margin) and consistent revenue growth from $2.2B in 2022 to $3.1B in 2025. Recent Q2 2026 earnings missed expectations at $4.94 EPS, but Q1 and Q4 2025 beat. Technicals show a bullish moving average signal with RSI at 59.48 neutral, while analyst consensus is strongly bullish with a $701.71 price target. The company maintains robust cash flow from operations of $1.6B in 2025.
Outlook remains positive driven by recurring revenue streams and market position, though high valuation (P/E 31.06) and debt levels ($4.51B long-term) pose risks. The upcoming Q3 2026 earnings on October 20, 2026, is a key catalyst. Investors should weigh strong fundamentals against premium pricing and macroeconomic sensitivity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →
